ARCUTIS BIOTHERAPEUTICS, INC. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2022-11-08
- ARCUTIS BIOTHERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2022-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2021-09-30 was $0.00.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 3 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 6 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |